Neuropharmacology Market Analysis and Reports | Italy Conference Series

Market Analysis - Neuropharmacology 2017

It is necessary to focus on neuropharmacology and the use of neuropharmaceuticals to transform brain processes in the way of enhancing memory, mood, sensation, thinking and attention in people. The neuropharmacology market is segmented on the basis of technology, application, and region. The global neurovascular devices/interventional neurology market is poised to reach $2,370.4 Million by 2020 growing at a CAGR of 8.4% from 2015 to 2020. The global neuromodulation market is expected to grow at a CAGR of 11.2% from 2015 to 2020, to reach $6.20 Billion by 2020 from $3.65 Billion in 2015. North America dominated the neuroscience market in 2013, with revenue valued at over USD 9,500 million. Asia-Pacific is expected to witness the fastest growth from 2015 to 2020 due to the presence of high unmet medical needs, rising patient awareness regarding nervous system disorders, and rising healthcare expenditures in emerging economies of India and China.

The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%. The global molecular diagnostics market was valued at almost $21.7 billion in 2014. The total market is projected to grow at a compound annual growth rate (CAGR) of 12.5% from 2015 through 2020 to reach nearly $25.2 billion by 2015 and $45.2 billion by 2020. The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019.

Market Capitalization of Neuropharmaceutical companies: In 2014, investors provided $3.3 billion into firms that are developing drugs for brain-destroying or psychiatric illnesses. Some big drug companies, including Johnson & Johnson, Roche and Novartis, are finding ways to reinvigorate their efforts. New medicines for severe depression, psychosis and schizophrenia could reach the market within the next few years, and treatments for Alzheimer’s, Parkinson’s and some forms of autism are a real possibility, too

The global mental health pharmaceutical market can be estimated at $80 billion in 2010. This market is expected to increase at a 1.9% compound annual growth rate (CAGR) over the forecast period to reach a value of $88 billion in 2015. The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%. 

The global market for Multiple Sclerosis (MS) disease-modifying products reached $10.1 billion in 2012 and nearly $10.9 billion in 2013. This market is expected to grow to nearly $14.2 billion in 2018 with a compound annual growth rate (CAGR) of 5.4% over the five-year period from 2013 to 2018. The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%. 

The combined direct and indirect cost of Parkinson’s, including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone.Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient. The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.

Neuropharmacology is the study of how drugs influence cellular function in the nervous system, and the neural mechanisms through which they influence behaviour. The studies are more concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Advanced studies are being made to improvise developments in drugs to treat numerous diverse neurological disorders, including neurodegenerative diseases known to be Parkinson's disease and Alzheimer's disease, pain, addiction, psychological disorders and many more.